Head-to-head · WeighScore
Open Water Rx vs Zealthy
The verdict
Open Water Rx takes it — 58.8/100 to 46.7/100.
Open Water Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Open Water Rx is a telehealth platform positioned around GLP-1 weight loss and longevity, per its own site.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Open Water Rx | Zealthy |
|---|---|---|
| WeighScore | 58.8/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #360 | #496 |
| Semaglutide | $249/mo (compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $339/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #360 · C
Strengths
- Combines weight-loss and longevity verticals in one brand
- Established brand domain
Where it loses points
- Limited public data — most details are gated behind signup or rendered only in JavaScript
- Pricing not disclosed
- GLP-1 options (semaglutide vs. tirzepatide, compounded vs. brand, injection vs. oral) not stated
- States-served list not disclosed
- Pharmacy partner not named
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.